Benefits of Morphine Gel for Pain Reduction in Patients With Cancer Wounds

Launched by INSTITUTO NACIONAL DE CANCER, BRAZIL · Apr 3, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of morphine gel compared to lidocaine gel in reducing pain for patients with cancer-related wounds, specifically in the breast or head and neck areas. The main goal is to find out if morphine gel provides better pain relief than lidocaine gel for these types of wounds. To participate, patients should have a malignant wound that is at least stage II, report a pain level of 3 or higher on a scale of 0 to 10, and have been admitted to the hospital for at least 48 hours. They also need to be using systemic morphine for pain management.

During the trial, patients will be asked to fill out questionnaires about their pain before and after the dressing change, which will be done by a nurse who does not know which gel is being used. This process will take place over three days. By comparing the pain relief from the two gels, researchers hope to determine which treatment is more effective. It's important for potential participants to know that certain types of wounds, like those with significant bleeding or ongoing radiation treatment, would not be eligible for this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Malignant neoplastic wound in breast or head and neck;
• • Malignant neoplastic wound with staging \>= II;
• • KPS \>=30%
• • Having at least 3 on the numerical pain rating scale (0-10);
• • Admission time equal to or greater than 48 hours.
• • Make use of systemic morphine.
• Exclusion Criteria:
• • Wound with fistula;
• • Wound with extensive coagulation necrosis (\>50% of wound area;
• • Exuding wound \> 1 (PUSH Scale);
• • Bleeding wound \>1 (VIBe Scale)
• • Ongoing radiotherapy on the wound.